

Electronic Supporting Information

Palladium Catalyzed Oxidative Suzuki Coupling Reaction of Indolizine at 3-position using Oxygen Gas as the Solo Oxidant

Huayou Hu, ^{*a, c} Yong Liu, ^a Juan Xu, ^a Yuhe Kan, ^a Chao Wang ^{*b} and Min Ji ^{*c}

^a Jiangsu Key Laboratory for Chemistry of Low-Dimensional materials, School of Chemistry and Chemical Engineering, Huaiyin Normal University, Huaian 223300, P. R. China, Fax: +86(517)83525100-1, E-mail: njuhhy@hotmail.com

^b MOE Engineering Research Center of Biomass Materials, School of Material Science and Engineering, Southwest University of Science and Technology, Mianyang 621010, P. R. China

^c State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, P. R. China

Table of Contents

General Methods and materials **S1**

Copies of Compounds' NMR spectra **S5**

General Methods and materials:

Unless otherwise noted, all commercial reagents and solvents were obtained from the commercial provider and used without further purification. ¹H NMR and ¹³C NMR spectra were recorded on Bruker 400 MHz spectrometers. Chemical shifts were reported relative to internal tetramethylsilane (δ 0.00 ppm) or CDCl₃ (δ 7.26 ppm) for ¹H NMR and CDCl₃ (δ 77.0 ppm) for ¹³C NMR. Flash column chromatography was performed on 300-400 mesh silica gels. Analytical thin layer chromatography was performed with pre-coated glass baked plates (250 μ) and visualized by fluorescence. HRMS were recorded on Bruker micrOTOF-Q spectrometer. IR spectra were recorded by Nicolet Avatar 360 spectrometer.

Substrates were synthesized according to the literature as below:

1. N. P. Buu-Hoi, P. Jacquignon, N. D. Xuong, D. Lavit, *J. Org. Chem.* **1954**, *19*, 1370-1375. (**1n** and **1o**)
2. L. Zhang, F. Liang, L. Sun, Y. Hu, H. Hu, *Synthesis*, **2000**, 1733-1737. (Other indolizines)

Characteristic data of new compounds

Compound 3aa (N,N-dimethyl-3-phenylindolizine-1-carboxamide): ¹H NMR (CDCl₃, 400 MHz): 8.23 (d, J = 7.1 Hz, 1H), 7.96 (d, J = 9.0 Hz, 1H), 7.54 (d, J = 7.2 Hz, 2H), 7.48 (t, J = 7.6 Hz, 2H), 7.38 (t, J = 7.2 Hz, 1H), 6.97 (s, 1H), 6.91 (dd, J = 8.8, 6.7 Hz, 1H), 6.61 (t, J = 6.6 Hz, 1H), 3.20 (s, 6H); ¹³C NMR (CDCl₃, 100 MHz): 167.8, 135.1, 131.6, 129.1, 128.5, 127.8, 125.1, 122.6, 120.3, 120.2, 114.6, 112.1, 107.5; IR (NaCl): 2958, 2924, 2853, 1600, 1541, 1494, 1511, 1456, 1411; HRMS (ESI): m/z calcd for C₁₇H₁₆N₂O: 265.1341 [M+H]⁺; found: 265.1341.

Compound 3ab (N,N-dimethyl-3-(4-(trifluoromethyl)phenyl)indolizine-1-carboxamide): ¹H NMR (CDCl₃, 400 MHz): 8.27 (d, J = 7.1 Hz, 1H), 7.98 (d, J = 9.1 Hz, 1H), 7.76 (d, J = 8.2 Hz, 2H), 7.68 (d, J = 8.2 Hz, 2H), 7.05 (s, 4H), 6.98 (dd, J = 8.8, 7.0 Hz, 1H), 6.69 (t, J = 6.6 Hz, 1H), 3.23 (s, 6H); ¹³C NMR (CDCl₃, 100 MHz): 167.5, 135.7, 135.2 (q, J = 5.1 Hz), 129.5 (q, J = 129.7 Hz), 128.3, 126.1 (q, J = 15.0 Hz), 123.6, 122.7, 122.4, 120.9, 120.4, 115.5, 112.7, 108.0; IR (NaCl): 2933, 1612, 1514, 1492, 1452; HRMS (ESI): m/z calcd for C₁₈H₁₅F₃N₂O: 333.1215 [M+H]⁺; found: 333.1218.

Compound 3ac (3-(4-chlorophenyl)-N,N-dimethylindolizine-1-carboxamide): ¹H NMR (CDCl₃, 400 MHz): 8.20 (d, J = 7.1 Hz, 1H), 7.98 (d, J = 9.1 Hz, 1H), 7.49 (s, 4H), 6.99 (s, 1H), 6.96 (dd, J = 8.6, 7.0 Hz, 1H), 6.66 (t, J = 6.7 Hz, 1H), 3.23 (s, 6H); ¹³C NMR (CDCl₃, 100 MHz): 167.6, 135.2, 133.6, 130.0, 129.7, 129.4, 123.8, 122.4, 120.5, 120.3, 114.8, 112.4, 107.7; IR (NaCl): 2927, 1609, 1538, 1509, 1477, 1450, 1411; HRMS (ESI): m/z calcd for C₁₇H₁₅ClN₂O: 299.0951 [M+H]⁺; found: 299.0952.

Compound 3ad (N,N-dimethyl-3-(*m*-tolyl)indolizine-1-carboxamide): ¹H NMR (CDCl₃, 400 MHz): 8.22 (d, J = 7.1 Hz, 1H), 7.96 (d, J = 9.1 Hz, 1H), 7.39 – 7.30 (m, 3H), 7.18 (d, J = 7.0 Hz, 1H), 6.95 (s, 1H), 6.89 (dd, J = 8.8, 6.8 Hz, 1H), 6.59 (t, J = 6.8 Hz, 1H), 3.19 (s, 6H), 2.41 (s, 3H);

^{13}C NMR (CDCl_3 , 100 MHz): 167.8, 138.8, 135.1, 131.5, 129.2, 129.0, 128.6, 125.5, 125.3, 122.8, 120.2, 120.2, 114.6, 112.0, 107.3, 21.5; IR (NaCl): 2924, 1605, 1510, 1449, 1400; HRMS (ESI): m/z calcd for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}$: 279.1497 $[\text{M}+\text{H}]^+$; found: 279.1492.

Compound 3ae (N,N-dimethyl-3-(p-tolyl)indolizine-1-carboxamide): ^1H NMR (CDCl_3 , 400 MHz): 8.23 (d, $J = 7.1$ Hz, 1H), 7.98 (d, $J = 9.1$ Hz, 1H), 7.45 (d, $J = 7.9$ Hz, 2H), 7.32 (d, $J = 7.8$ Hz, 2H), 6.97 (s, 1H), 6.96 (dd, $J = 8.5, 6.9$ Hz, 1H), 6.62 (t, $J = 6.6$ Hz, 1H), 3.23 (s, 6H), 2.45 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz): 167.8, 137.7, 135.0, 129.8, 128.7, 128.5, 125.2, 122.7, 120.2, 120.1, 114.4, 111.9, 107.3, 21.3; IR (NaCl): 2923, 1606, 1546, 1511, 1450, 1405; HRMS (ESI): m/z calcd for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}$: 279.1497 $[\text{M}+\text{H}]^+$; found: 279.1498.

Compound 3af (N,N-dimethyl-3-(o-tolyl)indolizine-1-carboxamide): ^1H NMR (CDCl_3 , 400 MHz): 8.04 (d, $J = 9.0$ Hz, 1H), 7.59 (d, $J = 7.0$ Hz, 1H), 7.43 – 7.30 (m, 4H), 6.95 (dd, $J = 8.6, 7.2$ Hz, 1H), 6.93 (s, 1H), 6.61 (t, $J = 6.7$ Hz, 1H), 3.25 (s, 6H), 2.15 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz): 167.9, 138.5, 134.7, 131.4, 130.6, 130.6, 128.9, 126.2, 124.1, 123.0, 120.2, 120.1, 114.8, 111.9, 106.4, 19.7; IR (NaCl): 3057, 3015, 2925, 1745, 1608, 1543, 1510, 1451, 1407; HRMS (ESI): m/z calcd for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_2$: 279.1497 $[\text{M}+\text{H}]^+$; found: 279.1497.

Compound 3ag (3-(4-methoxyphenyl)-N,N-dimethylindolizine-1-carboxamide): ^1H NMR (CDCl_3 , 400 MHz): 8.16 (d, $J = 7.0$ Hz, 1H), 7.96 (d, $J = 9.1$ Hz, 1H), 7.46 (d, $J = 8.6$ Hz, 2H), 7.04 (d, $J = 8.6$ Hz, 2H), 6.96 – 6.87 (m, 2H), 6.61 (t, $J = 6.7$ Hz, 1H), 3.89 (s, 3H), 3.22 (s, 6H); ^{13}C NMR (CDCl_3 , 100 MHz): 167.8, 159.4, 134.8, 130.1, 124.9, 124.0, 122.6, 120.2, 120.0, 114.5, 114.2, 111.9, 107.2, 55.4; IR (NaCl): 3047, 2933, 1711, 1609, 1546, 1490, 1453, 1408; HRMS (ESI): m/z calcd for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_2$: 295.1447 $[\text{M}+\text{H}]^+$; found: 295.1447.

Compound 3ah (3-(3,5-dimethylphenyl)-N,N-dimethylindolizine-1-carboxamide): ^1H NMR (CDCl_3 , 400 MHz): 8.26 (d, $J = 7.1$ Hz, 1H), 7.99 (d, $J = 9.1$ Hz, 1H), 7.18 (s, 2H), 7.05 (s, 1H), 6.97 (s, 1H), 6.93 (dd, $J = 8.8, 7.0$ Hz, 1H), 6.63 (t, $J = 6.7$ Hz, 1H), 3.23 (s, 6H), 2.41 (s, 6H); ^{13}C NMR (CDCl_3 , 100 MHz): 167.8, 138.7, 135.1, 131.5, 129.5, 126.2, 125.4, 122.9, 120.2, 120.1, 114.5, 111.9, 107.2, 21.4; IR (NaCl): 2920, 1602, 1540, 1510, 1451, 1404; HRMS (ESI): m/z calcd for $\text{C}_{19}\text{H}_{20}\text{N}_2\text{O}$: 293.1654 $[\text{M}+\text{H}]^+$; found: 293.1651.

Compound 3ai (3-(4-fluorophenyl)-N,N-dimethylindolizine-1-carboxamide): ^1H NMR (CDCl_3 , 400 MHz): 8.16 (d, $J = 7.0$ Hz, 1H), 7.96 (d, $J = 9.1$ Hz, 1H), 7.56 – 7.49 (m, 2H), 7.22 (t, $J = 8.6$ Hz, 2H), 6.98 (s, 1H), 6.96 (d, $J = 8.1$ Hz, 1H), 6.66 (t, $J = 6.7$ Hz, 1H), 3.25 (s, 6H); ^{13}C NMR (CDCl_3 , 100 MHz): 167.6, 162.3 (d, $J = 246.4$ Hz), 135.0, 130.4 (d, $J = 8.1$ Hz), 127.7 (d, $J = 3.4$ Hz), 124.0, 122.4, 120.28, 120.25, 116.1 (d, $J = 21.5$ Hz), 114.6, 112.2, 107.5; IR (NaCl): 2924, 2854, 1608, 1545, 1511, 1487, 1452, 1404; HRMS (ESI): m/z calcd for $\text{C}_{17}\text{H}_{15}\text{FN}_2\text{O}$: 283.1247 $[\text{M}+\text{H}]^+$; found: 283.1247.

Compound 3ga (tert-butyl 3-phenylindolizine-1-carboxylate): ^1H NMR (CDCl_3 , 400 MHz): 8.26 (d, $J = 7.1$ Hz, 1H), 8.22 (d, $J = 9.1$ Hz, 1H), 7.53 (d, $J = 7.2$ Hz, 2H), 7.48 (t, $J = 7.6$ Hz, 2H), 7.38 (t, $J = 7.2$ Hz, 1H), 7.26 (s, 1H), 7.03 (dd, $J = 8.6, 6.8$ Hz, 1H), 6.66 (t, $J = 6.4$ Hz, 1H), 1.64 (s, 9H); ^{13}C NMR (CDCl_3 , 100 MHz): 164.6, 135.9, 131.4, 129.1, 302.8, 128.7, 127.9, 126.1, 123.3, 121.8, 120.3, 116.4, 112.4, 106.0, 79.6, 28.6; IR (NaCl): 2973, 2926, 1687, 1543, 1511,

1449, 1420; HRMS (ESI): m/z calcd for $C_{19}H_{19}NO_2$: 294.1494 $[M+H]^+$; found: 294.1495.

Compound 3ha (ethyl 3-phenylpyrrolo[2,1-a]isoquinoline-1-carboxylate): 1H NMR ($CDCl_3$, 400 MHz): 9.84 (d, $J = 8.3$ Hz, 1H), 8.01 (d, $J = 7.4$ Hz, 1H), 7.61 (t, $J = 8.3$ Hz, 2H), 7.57 – 7.47 (m, 5H), 7.43 (t, $J = 7.1$ Hz, 1H), 7.31 (s, 1H), 6.92 (d, $J = 7.4$ Hz, 1H), 4.42 (q, $J = 7.1$ Hz, 2H), 1.44 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR ($CDCl_3$, 100 MHz): 165.5, 132.6, 131.3, 129.3, 129.0, 128.9, 128.2, 128.0, 127.6, 127.5, 127.3, 126.6, 126.1, 121.9, 116.5, 113.5, 109.1, 60.1, 14.6; IR (NaCl): 3065, 2979, 2930, 1698, 1644, 1604, 1551, 1506, 1459; HRMS (ESI): m/z calcd for $C_{21}H_{17}NO_2$: 316.1338 $[M+H]^+$; found: 316.1335.

Compound 3ia (3-phenylpyrrolo[2,1-a]isoquinoline-1-carbonitrile): 1H NMR ($CDCl_3$, 400 MHz): 8.89 (d, $J = 8.1$ Hz, 1H), 8.01 (d, $J = 7.4$ Hz, 1H), 7.72 – 7.61 (m, 2H), 7.61 – 7.44 (m, 6H), 7.01 (s, 1H), 6.97 (d, $J = 7.5$ Hz, 1H); ^{13}C NMR ($CDCl_3$, 100 MHz): 134.3, 130.2, 129.2, 129.1, 128.8, 128.7, 128.5, 128.1, 128.1, 127.2, 127.1, 125.1, 123.2, 121.8, 118.5, 115.4, 113.7; IR (NaCl): 3057, 2928, 2212, 1724, 1603, 1548, 1520, 1486, 1457; HRMS (ESI): m/z calcd for $C_{19}H_{12}N_2$: 269.1079 $[M+H]^+$; found: 269.1082.

Compound 3jb (dimethyl 3-(4-(trifluoromethyl)phenyl)indolizine-1,2-dicarboxylate): 1H NMR ($CDCl_3$, 400 MHz): 8.26 (d, $J = 9.1$ Hz, 1H), 8.04 (d, $J = 7.0$ Hz, 1H), 7.79 (d, $J = 8.1$ Hz, 2H), 7.66 (d, $J = 8.0$ Hz, 2H), 7.19 (dd, $J = 8.7, 7.0$ Hz, 1H), 6.80 (t, $J = 6.8$ Hz, 1H), 3.94 (s, 3H), 3.85 (s, 3H); ^{13}C NMR ($CDCl_3$, 100 MHz): 166.9, 164.4, 159.3 (q, $J = 1.2$ Hz), 135.7, 132.5 (q, $J = 1.2$ Hz), 131.0 (q, $J = 32.7$ Hz), 130.3, 126.9 (q, $J = 3.8$ Hz), 126.2 (q, $J = 3.7$ Hz), 125.9, 123.8 (q, $J = 95.5$ Hz), 123.5, 122.7, 120.5, 115.5, 114.1, 102.4, 52.7, 51.6; IR (NaCl): 3133, 2954, 2850, 1734, 1696, 1608, 1545, 1519, 1449; HRMS (ESI): m/z calcd for $C_{19}H_{14}F_3NO_4$: 378.0953 $[M+H]^+$; found: 378.0959.

Compound 3jc (dimethyl 3-(4-chlorophenyl)indolizine-1,2-dicarboxylate): 1H NMR ($CDCl_3$, 400 MHz): 8.22 (d, $J = 9.1$ Hz, 1H), 7.98 (d, $J = 7.0$ Hz, 1H), 7.48 (d, $J = 8.5$ Hz, 2H), 7.44 (d, $J = 8.5$ Hz, 2H), 7.12 (dd, $J = 8.4, 7.3$ Hz, 1H), 6.73 (t, $J = 6.8$ Hz, 1H), 3.89 (s, 3H), 3.80 (s, 3H); ^{13}C NMR ($CDCl_3$, 100 MHz): 166.6, 164.1, 135.4, 135.2, 131.4, 129.5, 127.3, 123.7, 123.7, 123.3, 122.3, 120.5, 113.8, 102.2, 52.5, 51.4; IR (NaCl): 2950, 1730, 1699, 1589, 1511, 1493, 1451; HRMS (ESI): m/z calcd for $C_{18}H_{14}ClNO_4$: 344.0690 $[M+H]^+$; found: 344.0693.

Compound 3je (dimethyl 3-(3-fluorophenyl)indolizine-1,2-dicarboxylate): 1H NMR ($CDCl_3$, 400 MHz): 8.25 (d, $J = 9.1$ Hz, 1H), 8.07 (d, $J = 7.1$ Hz, 1H), 7.50 (dd, $J = 14.0, 7.8$ Hz, 1H), 7.32 (d, $J = 7.6$ Hz, 1H), 7.25 (d, $J = 9.4$ Hz, 1H), 7.21 – 7.13 (m, 2H), 6.78 (t, $J = 6.7$ Hz, 1H), 3.93 (s, 3H), 3.85 (s, 3H); ^{13}C NMR ($CDCl_3$, 100 MHz): 165.4 (d, $J = 251.5$ Hz), 164.2, 161.7, 135.4, 130.9 (d, $J = 8.3$ Hz), 130.8 (d, $J = 8.5$ Hz), 125.7 (d, $J = 3.1$ Hz), 123.8, 123.45 (d, $J = 2.4$ Hz), 123.39, 122.5, 120.5, 116.9 (d, $J = 22.0$ Hz), 116.1 (d, $J = 20.9$ Hz), 113.8, 102.2, 52.6, 51.4; IR (NaCl): 2951, 2853, 1733, 1698, 1637, 1612, 1583, 1511, 1449; HRMS (ESI): m/z calcd for $C_{18}H_{14}FNO_4$: 328.0985 $[M+H]^+$; found: 328.0988.

Compound 3jf (dimethyl 3-(4-fluorophenyl)indolizine-1,2-dicarboxylate): 1H NMR ($CDCl_3$, 400 MHz): 8.24 (d, $J = 9.1$ Hz, 1H), 7.98 (d, $J = 7.0$ Hz, 1H), 7.51 (dd, $J = 8.4, 5.4$ Hz, 2H), 7.22 (app

t, $J = 8.5$ Hz, 2H), 7.14 (dd, $J = 8.7, 7.0$ Hz, 1H), 6.75 (t, $J = 6.7$ Hz, 1H), 3.92 (s, 3H), 3.83 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz): 165.5 (d, $J = 252.2$ Hz), 164.3, 161.8, 135.2, 132.1 (d, $J = 8.3$ Hz), 124.8 (d, $J = 3.4$ Hz), 124.0, 123.7, 123.4, 122.2, 120.4, 116.3 (d, $J = 21.6$ Hz), 113.7, 102.0, 52.5, 51.4; IR (NaCl): 2957, 2823, 2853, 1723, 1702, 1636, 1597, 1546, 1513, 1449; HRMS (ESI): m/z calcd for $\text{C}_{18}\text{H}_{14}\text{FNO}_4$: 328.0985 $[\text{M}+\text{H}]^+$; found: 328.0989.

Compound 3jg (dimethyl 3-(4-acetylphenyl)indolizine-1,2-dicarboxylate): ^1H NMR (CDCl_3 , 400 MHz): 8.24 (d, $J = 9.1$ Hz, 1H), 8.10 – 8.05 (m, 3H), 7.63 (d, $J = 8.1$ Hz, 2H), 7.15 (dd, $J = 8.7, 7.1$ Hz, 1H), 6.76 (t, $J = 6.8$ Hz, 1H), 3.90 (s, 3H), 3.81 (s, 3H), 2.65 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz): 197.3, 166.6, 164.0, 137.1, 135.7, 133.7, 129.9, 129.1, 124.0, 123.7, 123.4, 122.8, 120.6, 114.0, 102.6, 52.6, 51.4, 29.7; IR (NaCl): 2924, 2853, 1733, 1688, 1606, 1511, 1453; HRMS (ESI): m/z calcd for $\text{C}_{20}\text{H}_{17}\text{NO}_5$: 352.1185 $[\text{M}+\text{H}]^+$; found: 352.1183.

Compound 3ma (dibutyl 3-phenylindolizine-1,2-dicarboxylate): ^1H NMR (CDCl_3 , 400 MHz): 8.23 (d, $J = 9.1$ Hz, 1H), 8.01 (d, $J = 7.1$ Hz, 1H), 7.53- 7.40 (m, 5H), 7.09 (d, $J = 8.3, 6.8$ Hz, 1H), 6.69 (t, $J = 6.6$ Hz, 1H), 4.31 (t, $J = 6.6$ Hz, 2H), 4.18 (t, $J = 6.6$ Hz, 2H), 1.73 (quintet, $J = 7.1$ Hz, 2H), 1.57 – 1.41 (m, 4H), 1.19 (quintet, $J = 7.5$ Hz, 2H), 0.96 (t, $J = 7.4$ Hz, 3H), 0.81 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (CDCl_3 , 100 MHz): 166.4, 163.9, 135.3, 130.0, 129.1, 129.1, 129.0, 124.8, 123.5, 123.4, 122.5, 120.4, 113.4, 102.1, 65.2, 63.9, 31.0, 30.5, 19.3, 19.0, 13.8, 13.6; IR (NaCl): 2959, 2872, 1732, 1693, 1512, 1440, 1404; HRMS (ESI): m/z calcd for $\text{C}_{24}\text{H}_{27}\text{NO}_4$: 394.2018 $[\text{M}+\text{H}]^+$; found: 394.2016.

Copies of Compounds' NMR spectra



































































